These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases. La Salvia A; Brizzi MP; Muratori L; Trevisi E; Di Maio M; Scagliotti GV Endokrynol Pol; 2019; 70(4):380-383. PubMed ID: 30359462 [TBL] [Abstract][Full Text] [Related]
4. Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms. Melhorn P; Mazal P; Wolff L; Popov P; Kretschmer-Chott E; Haug A; Mayerhoefer ME; Raderer M; Kiesewetter B Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38214923 [TBL] [Abstract][Full Text] [Related]
5. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T; BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499 [TBL] [Abstract][Full Text] [Related]
6. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005 [TBL] [Abstract][Full Text] [Related]
7. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594 [TBL] [Abstract][Full Text] [Related]
8. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. Jeong H; Shin J; Jeong JH; Kim KP; Hong SM; Kim YI; Ryu JS; Ryoo BY; Yoo C ESMO Open; 2021 Jun; 6(3):100119. PubMed ID: 33901869 [TBL] [Abstract][Full Text] [Related]
9. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Strosberg JR; Fine RL; Choi J; Nasir A; Coppola D; Chen DT; Helm J; Kvols L Cancer; 2011 Jan; 117(2):268-75. PubMed ID: 20824724 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience. Douangprachanh S; Joo HJ; Park HM; Han N; Jang HY; Koh YH; Kim TH; Han SS; Park SJ; Lee WJ; Woo SM; Chun JW Korean J Intern Med; 2022 Nov; 37(6):1216-1222. PubMed ID: 36375489 [TBL] [Abstract][Full Text] [Related]
11. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors. Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077 [TBL] [Abstract][Full Text] [Related]
13. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours. Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Kobayashi N; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Hiroshima Y; Ichikawa Y Cancer Sci; 2021 May; 112(5):1936-1942. PubMed ID: 33453146 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. Abbasi S; Kashashna A; Albaba H Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906 [TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Claringbold PG; Price RA; Turner JH Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. Al-Toubah T; Morse B; Pelle E; Strosberg J Oncologist; 2021 Feb; 26(2):115-119. PubMed ID: 33225478 [TBL] [Abstract][Full Text] [Related]
18. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Kunz PL; Graham NT; Catalano PJ; Nimeiri HS; Fisher GA; Longacre TA; Suarez CJ; Martin BA; Yao JC; Kulke MH; Hendifar AE; Shanks JC; Shah MH; Zalupski MM; Schmulbach EL; Reidy-Lagunes DL; Strosberg JR; O'Dwyer PJ; Benson AB J Clin Oncol; 2023 Mar; 41(7):1359-1369. PubMed ID: 36260828 [TBL] [Abstract][Full Text] [Related]
19. The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy. Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Wang W; Liu L; Yu X J Neuroendocrinol; 2022 Jun; 34(6):e13112. PubMed ID: 35380016 [TBL] [Abstract][Full Text] [Related]
20. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]